Kinnevik KINV B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait or keep only a small tracking position; add only if NAV stabilizes in Q2 and/or Kinnevik delivers tangible portfolio actions/exits that validate marks and clarifies permanent CEO leadership.
Large NAV discount and strong net cash position provide endurance, yet uncertainty around unlisted valuations and execution keeps the signal at hold.
Sentiment has improved modestly after the CEO change, yet the market remains skeptical about the valuation of unlisted holdings.
HOLD is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 8 Jul 2026 — Kinnevik reported NAV of SEK 107/share (+6% QoQ, -17% H1) and net cash of SEK 7.4bn, alongside agreed disposals (Oda/YouScan) and cost-cut initiatives. Management changes include a new CEO on Aug 1 and the CFO leaving…
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Kinnevik is a Swedish investment company focused on listed and private growth businesses, mainly in digital health, software/SaaS, marketplaces and climate tech. The portfolio is growing operationally, but uncertainty around private valuations and recent write-downs have pressured the share price. The balance sheet is net-cash strong, yet the company needs to validate NAV through exits and more stable marks.
Bull case
New CEO may improve capital allocation and discipline, potentially narrowing the discount to NAV.
Bear case
Skepticism toward unlisted valuations persists and the company lacks a stable cash-generating anchor.
Why this signal
Large NAV discount and strong net cash position provide endurance, yet uncertainty around unlisted valuations and execution keeps the signal at hold.
Recent news
Helena Saxon assumed the CEO role on 1 August 2026. Samuel Sjöström left as CFO at the end of August and Caspar Sjöstrand became interim CFO from 1 September. Hannah Björk joins as IR director on the same date. Divestments of Oda and YouScan are expected to generate approximately SEK 133 million in proceeds during Q3. Spring Health, the largest holding, faces a proposed class action in California regarding labor law, which the company states does not affect the investment. Pareto Securities added the stock to its model portfolio.